Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bio-View Ltd specializes in developing innovative diagnostic solutions for cancer detection and monitoring, primarily through its proprietary technology that enhances the accuracy of cytological analysis. The company operates mainly in Israel, with a focus on expanding its market presence in Europe and North America through strategic partnerships and product development.
Bio-View generates revenue through the sale of diagnostic devices and related consumables, leveraging its proprietary technology to offer superior accuracy in cancer diagnostics. The company benefits from a recurring revenue model through consumables and maintenance services, which enhances customer retention and pricing power.
Regulatory approvals for new diagnostic products
Partnership announcements with healthcare providers
Market adoption rates of new technologies
Changes in reimbursement policies for diagnostic tests
Technological disruption from emerging diagnostic technologies
Regulatory changes impacting product approvals and market access
Increased competition from established players in the diagnostics space
Potential for new entrants with innovative technologies
Negative operating margins leading to cash flow challenges
High dependence on equity financing for operational sustainability
moderate - The demand for medical devices is somewhat insulated from economic downturns, but significant reductions in healthcare spending can impact sales.
Higher interest rates could increase the cost of financing for R&D and expansion efforts, potentially impacting future growth and valuation multiples.
minimal - The company has a manageable debt level with a debt/equity ratio of 0.30, indicating low reliance on external financing.
growth - Investors looking for high-growth potential in the healthcare sector, particularly in oncology diagnostics.
high - The stock has exhibited significant volatility, with a 1-year return of -65.6%, indicating a high-risk profile.
